R-Pharm US LLC

R-Pharm US LLC is a specialty pharmaceutical company established in 2014 and based in New Jersey. It focuses on developing and commercializing medicines for cancer and chronic immune diseases, including proprietary NME prodrugs intended to improve attributes of approved drugs. The company highlights IXEMPRA® (ixabepilone), acquired from Bristol-Myers Squibb, and describes research and development capabilities alongside its specialty pharmaceutical commercialization activities.